51108-29-3|4-Fluoroisoindoline-1,3-dione| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 51108-29-3 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 51108-29-3 ]

CAS No. :	51108-29-3
Formula :	C₈H₄FNO₂
M.W :	165.12
SMILES Code :	O=C1NC(C2=C1C=CC=C2F)=O
MDL No. :	MFCD13196660
InChI Key :	ROFGDCOBISHGRK-UHFFFAOYSA-N
Pubchem ID :	22064632

Safety of [ 51108-29-3 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 51108-29-3 ] Show Less

Physicochemical Properties

Num. heavy atoms	12
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	3.0
Num. H-bond donors	1.0
Molar Refractivity	41.78
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	46.17 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.93
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.82
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	0.75
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.68
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.94
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.22

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.75
Solubility	2.93 mg/ml ; 0.0178 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.37
Solubility	7.02 mg/ml ; 0.0425 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.05
Solubility	0.148 mg/ml ; 0.000895 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.73 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.45

Application In Synthesis of [ 51108-29-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 51108-29-3 ]

[ 51108-29-3 ] Synthesis Path-Downstream 1~35

1
[ 51108-29-3 ]
[ 540-73-8 ]
5-Fluoro-2,3-dimethyl-2,3-dihydro-phthalazine-1,4-dione [ No CAS ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 3351 - 3354.

2
[ 51108-29-3 ]
[ 1615-80-1 ]
2,3-Diethyl-5-fluoro-2,3-dihydro-phthalazine-1,4-dione [ No CAS ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 3351 - 3354.

3
[ 51108-29-3 ]
[ 109-84-2 ]
8-Fluoro-2-(2-hydroxy-ethyl)-2,3-dihydro-phthalazine-1,4-dione [ No CAS ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 3351 - 3354.

4
[ 51108-29-3 ]
[ 23928-46-3 ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 3351 - 3354.

5
[ 51108-29-3 ]
[ 60-34-4 ]
8-fluoro-2-methyl-2,3-dihydrophthalazine-1,4-dione [ No CAS ]

References: [1]Tetrahedron Letters,1996,vol. 37,p. 3351 - 3354.

7
[ 51108-29-3 ]
[ 743430-44-6 ]
(-)-tert-butyl(4-fluoro-1,3-dioxoisoindolin-2-yl)(4-methoxyphenyl)methylcarbamate [ No CAS ]
(+)-tert-butyl(4-fluoro-1,3-dioxoisoindolin-2-yl)(4-methoxyphenyl)methylcarbamate [ No CAS ]

References: [1]Chemical Communications,2007,p. 4477 - 4479.

8
[ 51108-29-3 ]
[ 743430-44-6 ]
tert-butyl(4-fluoro-1,3-dioxoisoindolin-2-yl)(4-methoxyphenyl)methylcarbamate [ No CAS ]

References: [1]Chemical Communications,2007,p. 4477 - 4479.

9
[ 117-21-5 ]
[ 51108-29-3 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; potassium fluoride; urea; In sulfolane; water; acetone;	EXAMPLE 2 500 parts (2.739 moles) of <strong>[117-21-5]3-chlorophthalic anhydride</strong> and 49.9 parts of thionyl chloride are added to 820 parts of sulfolane, while stirring. The mixture is stirred for 30 minutes at 100 C., after which the evolution of gas is complete. Excess thionyl chloride is stripped off under reduced pressure from a water pump, after which 175 parts of potassium fluoride are added and stirring is continued for 6 hours at 210 C. The mixture is cooled to 60 C., and 82 parts (1.37 moles) of urea are then added. The mixture is stirred for 1 hour 30 minutes at 130 C., when evolution of gas is complete, after which stirring is continued for a further 15 minutes at 170 C. The mixture is then cooled to room temperature, 300 parts of acetone are added, while stirring, and the predominantly inorganic precipitate is filtered off under suction. The filtrate is freed from acetone in a rotary evaporator, and the residue is then distilled over a 10 cm packed column at a bath temperature of 140-170 C. under 0.4 mbar. The distillation residue is stirred with water, and the product is filtered off under suction, washed with methyl tert.-butyl ether and dried, 382 parts (84.5% of theory) of 3-fluorophthalimide of melting point 176-179 C. being obtained. By treating the inorganic residue with 300 parts of acetone, separating off the extract and evaporating it down under reduced pressure, a further 29 parts (6.8% of theory) of 3-fluorophthalimide of melting point 166-178 C. are isolated.

References: [1]Patent: US4680412,1987,A .

10
[ 652-39-1 ]
[ 51108-29-3 ]

Yield	Reaction Conditions	Operation in experiment
95%	With formamide; In neat (no solvent); for 0.333333h;Milling; Heating; Green chemistry;	General procedure: A mixture of anhydride (1 mmol), formamide (1.1 mmol for monoanhydrides and 2.2 mmol for dianhydrides) and 1 g clay was ground together in a mortar using pestle for the time described in Table 1. The reaction mixture was warmed. After completing the reaction (monitored by TLC, after observing no anhydride presence in the reaction mixture), the product was extracted by washing clay with chloroform (2×15 mL), the solvent was removed under vacuum to afford the relevant N-unsubstituted cyclic imide. The solid imide was washed thoroughly with water, dried, and then recrystallized from ethanol. The solid clay portion was washed with methanol and dried at 120 C under a reduced pressure to be reused in the subsequent reactions which showed the gradual decrease in the activity (Table 1). Isolated products were characterized by melting points, IR, 1H NMR spectrometric data and were compared with the literature or authentic samples.
83%	With formamide; at 130℃; for 1h;Inert atmosphere;	Under argon, 10.0 g (60.2 mmol) of 4-fluoro-2-benzofuran-1,3-dione were stirred at 130 C. in 50 ml of formamide for 1 h. The cooled reaction mixture was then added to ice-water. A solid precipitated out. This solid was filtered off with suction and washed with water. The product was dried under high vacuum. This gave 8.3 g (83% of theory) of the target compound.LC-MS (method 11): Rt=0.57 min; m/z=166 (M+H)+.1H-NMR (400 MHz, DMSO-d6): δ=11.47 (br. s, 1H), 7.87 (td, 1H), 7.69-7.61 (m, 2H).
73%	With formamide; at 125℃; for 1 - 5h;	The best result occurs when the starting material is run 0.5 M in formamide and heated to 125 C for 1 to 5 h depending on scale. Starting material is not soluble in fonnamide until the temperature is > 60 C. Upon completion of reaction as monitored by LC/MS (apcineg), the heat is removed and 3 times the volume of the reaction of water is added. Next, the reaction is allowed to warm to room temperature and stirred until a pale yellow precipitate has formed. The yellow solid product is filtered off and washed with water before drying overnight to give yields between 70-77 %.

With ammonia; In water; at 280℃; for 0.5h;

In a 50 ml flask was placed 3-Fluorophthalic anhydride (1.0 g, 6 mmol) and aqueous NH3 (1.6 g, 24 mmol). The mixture was heated to 280 0C within 30 minutes and then the flask was cooled to room temperature. 0.93 g of compound 13 were isolated as a yellow solid. LC-MS (ESI, positive): 166 [M+H]+.

References: [1]Journal of the Chilean Chemical Society,2017,vol. 62,p. 3501 - 3504.
[2]Patent: US2011/34450,2011,A1 .Location in patent: Page/Page column 114.
[3]Patent: WO2005/37214,2005,A2 .Location in patent: Page/Page column 178.
[4]Patent: WO2008/86161,2008,A1 .Location in patent: Page/Page column 52.
[5]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4159 - 4162.

11
[ 51108-29-3 ]
[ 127168-78-9 ]

Yield	Reaction Conditions	Operation in experiment
> 80%		To the starting material in a round bottom flask was added 4 equivalents of 1 M BH3- THF drop wise using an addition funnel to form a golden solution which upon heating and stirring turned copper in color. The reaction was then heated at reflux for 18 h. [00590] The reaction is then cooled to room temperature (rt) and then to 0 C in an ice bath. 4 equivalents of MeOH are added drop wise and the ice bath removed so quenched reaction can warm to rt. Reaction color turns dark during this warming process. Next, 6 N HC1 was added drop wise at rt until pH paper showed reaction to be acidic and the reaction refluxed (63 C) for 1 h. The reaction was then cooled to rt. At this point the reaction was concentrated and washed with Et2O (2x) and DCM (2x). The aqueous layer was then brought to pH = 11 with NaOH pellets. More water was added and the aqueous layer was extracted with ether (4x). The combined extracts were dried over Na2S04 and concentrated to give a light tan colored oil product, which was used directly. Mass recovery is always slightly higher than theoretical, but material is used crude like this to give > 80 % yield in the next step.
		To compound 13 (4.0 g, 24.2 mmol) in a round bottom flask was added 1M BH3 in THF solution (97 mL, 97 mmol) dropwise at room temperature. The resulting solution was warmed to reflux for 18 hours. Then the reaction mixture was cooled to 0 0C and methanol (3.1 g, 97 mmol) was added dropwise. The resulting mixture was warmed up to room temperature and then 6 M HCl was added dropwise to adjust the reaction pH to 3, followed by refluxed for 1 hour. <n="54"/>After the reaction was completed, the solvents were removed under reduced pressure to give an brown oil. The residue was washed with Et2O (2x50 ml) and CH2Cl2 (2x50 mL). The aqueous phase was adjusted to pH 11 with NaOH. Then the aqueous layer was extracted with ether (4x50 mL), dried over Na2SO4, and filtered. Solvents were removed under reduced pressure to give a dark red residue. The pure compound was purified by distillation (2 mmHg, 45 0C) to give compound 14 (1.2 g).

References: [1]Patent: WO2005/37214,2005,A2 .Location in patent: Page/Page column 179.
[2]Patent: WO2008/86161,2008,A1 .Location in patent: Page/Page column 52-53.
[3]Bioorganic and Medicinal Chemistry Letters,2008,vol. 18,p. 4159 - 4162.

12
[ 51108-29-3 ]
[ 1192042-15-1 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium tetrahydroborate; ethanol; at 0 - 20℃;	7458 mg (12.1 mmol) of sodium borohydride were added a little at a time to a suspension, cooled to 0 C., of 4.0 g (24.2 mmol) of 4-fluoro-1H-isoindole-1,3(2H)-dione in 40 ml of ethanol. After the addition had ended, cooling was removed and the mixture was warmed to RT. After 20 min of stirring, a further 458 mg (12.1 mmol) of sodium borohydride were added at RT. After a further 30 min at RT, 1 N hydrochloric acid was added carefully to the reaction mixture and the pH was adjusted to neutral. The mixture was concentrated under reduced pressure and the residue was taken up in dichloromethane and filtered through Celite. The collected filtrate was concentrated under reduced pressure. This gave 4.05 g of 4-fluoro-3-hydroxy-2,3-dihydro-1H-isoindol-1-one, which was directly reacted further as crude product.4.05 g (about 24.2 mmol) of 4-fluoro-3-hydroxy-2,3-dihydro-1H-isoindol-1-one were initially charged in 10 ml of dichloromethane, 22.4 ml (290.8 mmol) of trifluoroacetic acid and 7.7 ml (48.5 mmol) of triethylsilane were added and the mixture was stirred at RT overnight. The reaction mixture was then concentrated and the residue was dissolved in dichloromethane and washed with sodium bicarbonate solution. The crude product was purified by chromatography on silica gel (mobile phase cyclohexane/ethyl acetate 3:1 to 1:1). This gave 890 mg (24.2% of theory) of the target compound.LC-MS (method 12): Rt=1.18 min; m/z=152 (M+H)+.1H-NMR (400 MHz, DMSO-d6): δ=8.77 (br. s, 1H), 7.58-7.51 (m, 2H), 7.49-7.40 (m, 1H), 4.46 (s, 2H).

References: [1]Patent: US2011/34450,2011,A1 .Location in patent: Page/Page column 114.

13
[ 51108-29-3 ]
[ 366452-96-2 ]

References: [1]Patent: US2011/34450,2011,A1 .

14
[ 67-56-1 ]
[ 51108-29-3 ]
[ 144851-82-1 ]
[ 1356116-39-6 ]
[ 1356116-41-0 ]

References: [1]Organic Letters,2012,vol. 14,p. 946 - 949.

15
[ 67-56-1 ]
[ 51108-29-3 ]
[ 1356116-39-6 ]
[ 1356116-41-0 ]

References: [1]Chemical Communications,2012,vol. 48,p. 8574 - 8576.

16
[ 51108-29-3 ]
2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-4-fluoroisoindoline-1,3-dione hydrochloride [ No CAS ]

References: [1]European Journal of Medicinal Chemistry,2018,vol. 145,p. 74 - 85.

17
[ 110-52-1 ]
[ 51108-29-3 ]
2-(4-bromobutyl)-4-fluoroisoindoline-1,3-dione [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
85%	With potassium carbonate; In acetone; for 2h;Reflux;	General procedure: Phthalimide 6a (148mg, 1mmol), 124 1,4-dibromobutane (1.080g, 5mmol), 12 potassium carbonate (276mg, 2mmol) was added to 115 acetone (3mL), and the reaction mixture was refluxed for 2h. After cooling to room temperature, the reaction mixture was purified by column chromatography using 125 PE: acetone (40:1) as eluent to give 126 7a (260mg, 92%) as a white solid.

References: [1]European Journal of Medicinal Chemistry,2018,vol. 145,p. 74 - 85.

18
[ 51108-29-3 ]
4-(4-fluoro-1,3-dioxoisoindolin-2-yl)-N-(5-phenylpyridin-2-yl)butanamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 870 - 872.

19
[ 51108-29-3 ]
[ 56-12-2 ]
C₁₂H₁₀FNO₄ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With acetic acid; for 3h;	General procedure: Phthalic anhydride or its derivatives (2.0 mmol) and 4-aminobutyric acid (2.0 mmol) were added to glacial acetic acid (10 mL) and heated to 100 C for 3 h. The reaction was quenched with water (10 mL) and was adjusted to pH 6-8 with NaOH (0.1 mol/L). The mixture was extracted with dichloromethane (10 mL × 3), and the organic layer was washed with aq. NaHCO3, and water and then evaporated to afford intermediate.

References: [1]Bioorganic and Medicinal Chemistry Letters,2019,vol. 29,p. 870 - 872.

20
[ 51108-29-3 ]
N‐(pyrimidin‐2‐yl)indoline [ No CAS ]
4-fluoro-2-(1-(pyrimidin-2-yl)indolin-7-yl)isoindoline-1,3-dione [ No CAS ]

References: [1]Advanced Synthesis and Catalysis,2019,vol. 361,p. 3108 - 3113.

21
[ 51108-29-3 ]
4-((6-aminohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione trifluoroacetic acid salt [ No CAS ]